Barrier Proteins in Tumors are Possible Key to Immunotherapy Success

Reading Time: 1 minutes

By comparing variations in protein expression in tumor samples from a single melanoma patient, researchers from the Johns Hopkins Bloomberg~Kimmel Institute and the Memorial Sloan-Kettering Cancer Center say their findings have the potential to reveal some of the mechanisms underlying response or resistance to immunotherapy drugs. The “proof of concept” findings, published online Feb. 13, 2017, in Clinical Cancer Research, point to distinct variations not in the genetic code of each tumor sample, but in the expression levels of certain proteins encoded by normal genes.

Leave a Reply

Your email address will not be published. Required fields are marked *